| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
20(R)-Ginsenoside Rg2 targets multiple signaling pathways. It has been shown to protect H9c2 cells against H2O2-induced injury through its antioxidant and anti-apoptotic actions. It suppresses hepatic glucose production via AMPK-induced phosphorylation of GSK3β and induction of SHP gene expression. This suggests a potential therapeutic role for type 2 diabetes. It also modulates the PI3K/Akt and NF-κB pathways, contributing to its neuroprotective, cardioprotective, and anti-inflammatory effects. Its anticancer activity is evidenced by its inhibitory effects on lung cancer cells.
|
|---|---|
| ln Vitro |
In vitro, 20(R)-Ginsenoside Rg2 shows inhibitory effects on lung cancer NCI-H1650 cells, indicating its anticancer activity. It protects H9c2 cells against H2O2-induced injury through its antioxidant and anti-apoptotic actions. It also suppresses hepatic glucose production via AMPK-induced phosphorylation of GSK3β and induction of SHP gene expression. These in vitro studies demonstrate its diverse biological activities, including anticancer, cardioprotective, and anti-diabetic effects.
|
| ln Vivo |
In vivo activity data for 20(R)-Ginsenoside Rg2 is limited in publicly available literature. As a compound with potent neuroprotective, cardioprotective, anti-fatigue, and anti-inflammatory properties in vitro, it is hypothesized to exhibit similar effects in animal models. However, specific in vivo efficacy studies, including pharmacokinetic and pharmacodynamic parameters, have not been detailed in the available sources. Further research is needed to fully characterize its in vivo activity and therapeutic potential.
|
| Enzyme Assay |
For cell-free enzyme assays, the activity of 20(R)-Ginsenoside Rg2 can be studied using kinase activity assays for its targets, such as AMPK or PI3K. The assay involves incubating the compound with the purified kinase and its substrate in the presence of ATP. The phosphorylation of the substrate is measured using radioactive or fluorescence-based methods. The IC50 value for kinase inhibition can be calculated from a dose-response curve.
|
| Cell Assay |
For in vitro cellular assays, the anticancer activity of 20(R)-Ginsenoside Rg2 is typically assessed in cancer cell lines, such as NCI-H1650 lung cancer cells. Cells are seeded in multi-well plates and treated with varying concentrations of the compound for a defined period. Cell viability is measured using MTT, MTS, or SRB assays, and the IC50 value is calculated. Its cardioprotective effect can be assessed in H9c2 cells exposed to H2O2-induced oxidative stress, where cell viability and apoptotic markers are measured.
|
| Animal Protocol |
For in vivo studies, 20(R)-Ginsenoside Rg2 could be administered orally or intraperitoneally in rodent models of cancer, diabetes, or cardiovascular disease. In a xenograft model, its anti-tumor efficacy would be assessed by measuring tumor volume over time. In a model of type 2 diabetes, its effect on hepatic glucose production could be assessed by measuring blood glucose levels and performing glucose tolerance tests.
|
| ADME/Pharmacokinetics |
20(R)-Ginsenoside Rg2 has a molecular formula of C42H72O13 and a molecular weight of 785.01 g/mol. Its CAS number is 80952-72-3. It is typically supplied as a powder. It is soluble in DMSO and ethanol. For in vitro studies, stock solutions are prepared in DMSO. For in vivo administration, it can be formulated in suitable vehicles. Storage is recommended at -20°C, protected from light. Its purity is typically >98% for research use.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is publicly available. As a natural ginsenoside, it is generally considered to have low toxicity, but standard toxicological studies would be required for drug development. In vitro cytotoxicity assays in various cell lines are typically performed alongside efficacy studies to confirm that the observed effects are not due to a general reduction in cell viability.
|
| References | |
| Additional Infomation |
Ginsenoside Rg2 is a ginsenoside found in plants of the genus Panax. Its structure is dammarane-type, with hydroxyl groups substituted at positions 3β, 6α, 12β, and 20 (pro-S position). Specifically, the hydroxyl group at position 6 is converted to the corresponding α-L-rhamnosyl-(1→2)-β-D-glucopyranoside, and a double bond is introduced at positions 24-25. It is a plant metabolite with cardioprotective and anticoagulant effects. It is a β-D-glucoside, 12β-hydroxysteroid, 3β-hydroxysteroid, ginsenoside, tetracyclic triterpenoid, disaccharide derivative, 20-hydroxysteroid, and 3β-hydroxy-4,4-dimethylsteroid. It is derived from the hydride of dammarane. Ginsenoside Rg2 has been reported in Gynostemma pentaphyllum, ginseng, and other organisms with relevant data. See also: 20(S)-Ginsenoside Rg2 (note moved to).
20(R)-Ginsenoside Rg2 is a research-grade compound and is not approved for any therapeutic use. It serves primarily as a valuable pharmacological tool for studying the mechanisms of ginsenosides. Its mechanism of action involves the modulation of AMPK, PI3K/Akt, and NF-κB pathways. Its anticancer, cardioprotective, and anti-diabetic activities make it a compound of interest for drug discovery. No clinical trials have been reported. |
| Molecular Formula |
C42H72O13
|
|---|---|
| Molecular Weight |
785.0133
|
| Exact Mass |
784.497
|
| CAS # |
80952-72-3
|
| PubChem CID |
21599924
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
881.0±65.0 °C at 760 mmHg
|
| Flash Point |
486.6±34.3 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.593
|
| LogP |
6.78
|
| Hydrogen Bond Donor Count |
9
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
55
|
| Complexity |
1390
|
| Defined Atom Stereocenter Count |
21
|
| SMILES |
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2O[C@H]3C[C@@]4([C@H](C[C@H]([C@H]5[C@]4(CC[C@@H]5[C@@](C)(CCC=C(C)C)O)C)O)[C@@]6([C@@H]3C([C@H](CC6)O)(C)C)C)C)CO)O)O)O)O)O
|
| InChi Key |
AGBCLJAHARWNLA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C42H72O13/c1-20(2)11-10-14-42(9,51)22-12-16-40(7)28(22)23(44)17-26-39(6)15-13-27(45)38(4,5)35(39)24(18-41(26,40)8)53-37-34(32(49)30(47)25(19-43)54-37)55-36-33(50)31(48)29(46)21(3)52-36/h11,21-37,43-51H,10,12-19H2,1-9H3
|
| Chemical Name |
2-[2-[[3,12-dihydroxy-17-(2-hydroxy-6-methylhept-5-en-2-yl)-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-6-yl]oxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-6-methyloxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~127.39 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.18 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.18 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.18 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2739 mL | 6.3693 mL | 12.7387 mL | |
| 5 mM | 0.2548 mL | 1.2739 mL | 2.5477 mL | |
| 10 mM | 0.1274 mL | 0.6369 mL | 1.2739 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
